Russian Federation
Russian Federation
Russian Federation
256 patients with type 2 diabetes and arterial hypertension (AH) were examined. The blood aldosterone level was determined in all patients, 24-hour blood pressure monitoring (BPM) and echodopplercardiography were performed, and the parameters of arterial vascular stiffness were studied. Results. In patients with type 2 diabetes and hypertension, the level of aldosterone in the blood ranged from 25 to 186 pg / ml, which corresponded to the reference norm. Patients with a level of aldosterone less than 25 percentile accounted for 15% of the examined - group I; Group II - patients with middle aldosterone levels (25-75 percentiles) - 46%; with a level more than 75 percentile - 39%, were included in group III. In the studied groups, office blood pressure (BP) did not depend on the level of aldosterone, however, in patients with both aldosterone levels above the 75th percentile and below the 25th percentile, an increase in the average daily pulse BP and an insufficient degree of nighttime BP reduction were revealed during BPM. Similarly, in groups I and III, there was a statistically significant increase in arterial stiffness indicators, compared with individuals with an average level of aldosterone. Disorders of diastolic function and LV hypertrophy were also more pronounced in groups of patients with aldosterone levels less than the 25th and more than 75th percentile. Conclusion. In patients with type 2 diabetes, the level of blood aldosterone less than the 25th and more than 75th percentile within the reference norm is associated with a greater severity of myocardial and arterial vessel remodeling processes.
aldosterone, myocardial remodeling, arterial hypertension, type 2 diabetes
1. Mirabito Colafella K. M, Danser AHJ. Recent advances in angiotensin research. Hypertension. 2017;69:994-999. doi:0.1161/ HYPERTENSIONAHA.117.08931.
2. Neves M. F., Cunha A. R., Cunha M. R., Gismondi R. A., Oigman W. The Role of Renin- Angiotensin-Aldosterone System and Its New Components in Arterial Stiffness and Vascular Aging. High Blood Pressure & Cardiovascular Prevention. 2018;25:137-145. doihttps://doi.org/10.1007/s40292-018-0252-5.
3. Aroor A. R., Demarco V. G., Jia G., Sun Z., Nistala R., Meininger G. A. The role of tissue renin- angiotensin-aldosterone system in the development of endothelial dysfunction and arterial stiffness. Frontiers in endocrinology. 2013;4:161. doi: 10.3389/ fendo.2013.00161.
4. Lother A., Hein L. Vascular mineralocorticoid receptors: linking risk factors, hypertension, and heart disease. Hypertension. 2016;68:6-10. doi: 10.1161/ HYPERTENSIONAHA.116.07418.
5. Briet M., Schiffrin E. L. Vascular actions of aldosterone. Journal of vascular research. 2013;50:89- 99. doi:https://doi.org/10.1159/000345243.
6. Jia G, Aroor A R, Hill M A, Sowers J R. Role of Renin-Angiotensin-Aldosterone System Activation in Promoting Cardiovascular Fibrosis and Stiffness. Hypertension. 2018;72:537-548. doi:10.1161/ HYPERTENSIONAHA.118.11065.
7. Solomon S. D., Claggett B., Lewis E. F., Desai A., Anand I., Sweitzer N. K. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. European Heart Journal. 2016;37 (5):455-62. doi:https://doi.org/10.1093/eurheartj/ehv464.
8. Ribeiro-Oliveira A Jr, Nogueira A I, Pereira R M, Boas W W, Dos Santos R A, Simhes e Silva A C. The renin-angiotensin system and diabetes: An update. Vascular Health and Risk Management. 2008;4(4):787- 803. doihttps://doi.org/10.2147/VHRM.S1905.
9. Griffin T. P., Wall D., Browne G. A., Dennedy M. C., O’Shea P. M. Associations between glycaemic control and activation of the renin-angiotensin-aldosterone system in participants with type 2 diabetes mellitus and hypertension. Annals of clinical biochemistry. 2018;55(3):373-84. doihttps://doi.org/10.1177/0004563217728964.
10. Price D. A., Porter L. E., Gordon M., Fisher NDL, De`Oliveira JMF, Laffel LMB. The Paradox of the Low-Renin State in Diabetic Nephropathy. Journal Of The American Society Of Nephrology. 1999;10(11):2382-2391. ISSN: 1046-6673.
11. Pitt B., Williams G., Remme W., Martinez F., Lopez-Sendon J., Zannad F. The EPHESUS Trial:Eplerenone in Patients with Heart Failure Due to Systolic Dysfunction Complicating Acute Myocardial Infarction. Cardiovascular Drugs and Therapy. 2001;15:79-87. doi:https://doi.org/10.1023/A:1011119003788.
12. Pitt B. ACE inhibitor co-therapy in patients with heart failure: Rationale for the Randomized Aldactone Evaluation Study (RALES). European Heart Journal. 1995;16(1):107-110. doi: https://doi.org/10.1093/eurheartj/16. suppl_N.107.
13. Dedov I. I., Shestakova M. V., Mayorov A. Yu., Shamhalova M. Sh., Nikonova T. V., Suhareva O. Yu. Algoritmy specializirovannoy medicinskoy pomoschi bol'nym saharnym diabetom. Saharnyy diabet. 2019;22(S.1):1-121. doi:https://doi.org/10.14341/DM221S1.
14. Kobalava Zh. D., Konradi A. O., Nedogoda S. V., Shlyahto E. V., Arutyunov G. P., Baranova E. I. Arterial'naya gipertenziya u vzroslyh. Klinicheskie rekomendacii 2020. Rossiyskiy kardiologicheskiy zhurnal. 2020;25(3):37-86. doihttps://doi.org/10.15829/1560-4071- 2020-3-3786.
15. Chobanian A. V., Bakris G. L., Black H. R., Cushman W. C., Green L. A., Izzo Jr. JL et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. Jama. 2003;289(19):2560- 71. doihttps://doi.org/10.1001/jama.289.19.2560.
16. Lang R. M., Badano L. P., Mor-Avi V., Afilalo J., Armstrong A., Ernande L. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging, European Heart Journal - Cardiovascular Imaging. 2015;16(30):233-271. doi:https://doi.org/10.1093/ehjci/jev014.
17. Vlachopoulos C., Aznaouridis K., Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. Journal of the American College of Cardiology. 2010;55:1318-1327. doi: https://doi.org/10.1016/j. jacc.2009.10.061.
